/
Infectious Disease
Human Immunodeficiency Virus (HIV)
5
Pipeline Programs↗
7
Active Trials↗
5
Companies Involved↗
Human Immunodeficiency Virus (HIV) is an early-stage landscape with 5 programs across 5 companies. The most active players are Merck & Co.. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 11
Phase 23
Phase 31
Approved
No programs
Analysis
Trial Status
11
clinical trials
Completed3 · 27%
Recruiting2 · 18%
Active, not recruiting2 · 18%
Not yet recruiting2 · 18%
Withdrawn1 · 9%
Enrolling by invitation1 · 9%
Clinical Trials
Trial Activity
11 trials
Reversing the Biological Clock: Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV
Enrolling by invitation·NNational Taiwan University Clinical Trial Center·Approved·NCT07707778·60 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)